NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
QLOSI (pilocarpine hydrochloride) by Orasis Pharmaceuticals is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 2023.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QLOSI (pilocarpine hydrochloride) is a cholinergic parasympathomimetic agent administered as an ophthalmic solution that stimulates exocrine gland secretion, particularly salivary flow. It is indicated for xerophthalmia and xerostomia in head and neck cancer patients and Sjögren's syndrome patients. The drug works by acting as a muscarinic agonist to enhance salivary and lacrimal gland function.
Growth10.9 years to LOE
Recent approval (October 2023) positions QLOSI in early growth phase with opportunity to build brand awareness and market share in niche ophthalmology and oncology segments.
Mechanism of Action
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on QLOSI at Orasis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.